Novo Nordisk Stock Gains as FDA Cracks Down on Telehealth Firms Over GLP-1 Drug Claims
Novo Nordisk shares climbed more than 3% following regulatory action against 30 telehealth companies accused of misleading marketing practices. The FDA issued warning letters targeting firms promoting compounded semaglutide and tirzepatide as generic alternatives to branded drugs like Wegovy and Zepbound.
This marks the agency's second enforcement wave under drug advertising guidelines established during the previous administration. Violators face 15-day deadlines to submit corrective action plans. Citi Research noted the FDA's heightened scrutiny, recalling its recent referral of Hims & Hers to the Department of Justice.
The regulatory clampdown underscores ongoing tensions between pharmaceutical innovators and compounding pharmacies. While acknowledging compounded drugs' role in addressing medication shortages, the FDA maintains they lack the rigorous approval process required for generics.
